LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, today announced it has hired Paul Y. Song, M.D., as Chief Medical Officer to oversee translational and clinical research programs at Cynvenio.
Dr. Song will be responsible for global clinical utility activities including trial definition, institutional partner selection and patient stratification. He will also coordinate global activities with partners abroad, especially in Europe and China.
A respected clinician and seasoned medical executive with more than two decades experience in the field of oncology, Dr. Song is also on the faculty at Cedars Sinai Medical Center, in the Samuel Oschin Cancer Center department of radiation oncology and biomedical sciences. He also serves as Chief Medical Officer at AT-Gen Co. Ltd, where he oversees all clinical aspects of the company’s NK-Vue, an ELISA-based blood test which measures natural killer cell activity. Dr. Song is a Senior Adviser at Berg Health, where he previously served as its Chief Medical Officer. Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University.
“Paul’s proven ability to tackle difficult medical, scientific and technology problems, together with his hands-on success treating patients as a radiation-oncologist at Cedars Sinai for many years, make him an excellent fit for the role of our first CMO,” said André de Fusco, Cynvenio’s Chief Executive Officer. “Like all of us at Cynvenio, Paul is passionate about making a real difference in cancer treatment, particularly the ability to marry new technology with medical practice to bring tangible benefits to patients and physicians. We are proud to have him join our team.”
“Cynvenio was founded on years of cutting edge scientific research in the area of cancer genetics and biomarkers, and I’m excited to join the team and help our technology reach its full clinical utility in providing an improved personalized and actionable cancer diagnosis,” said Dr. Song. “I am confident that Cynvenio’s unique ability to isolate and interrogate both cell-free DNA and circulating tumor cells can dramatically redefine how patients with subclinical and/or widely metastatic disease are treated with more effective targeted therapies. This is especially relevant to those who have progressed despite numerous courses of treatment due to surviving cancer clones that no longer resemble the original primary tumor.”
About Cynvenio Biosystems, Inc.
Cynvenio is a commercial stage clinical diagnostics company that leverages its proprietary LiquidBiopsy® multi-template technology for the molecular characterization of tumor cells from a standard blood draw. Commercial labs and research institutions are powered by Cynvenio’s LiquidBiopsy platform, which includes automated instrumentation, consumables/reagents, patient sample kits, and bioinformatics for sequencing rare cell populations. Oncology practices and individual physicians can also access the LiquidBiopsy system with zero upfront investment by ordering the ClearID™ blood test from Cynvenio’s CLIA lab or its clinical partners. ClearID and LiquidBiopsy are cornerstones in the emerging field of genomic peripheral blood monitoring. They are used to rapidly assess patients’ evolving mutations in support of precision medicine strategies. ClearID is reimbursable in the United States.
LiquidBiopsy® and ClearID™ are registered trademarks of Cynvenio Biosystems, Inc.